Formulari Ubat KKM (FUKKM)

# Generic Name MDC Category Indications Pres. Restrictions Dosage
811 Interferon Beta-1a 22 mcg Injection L03AB07000P5001XX A* Multiple sclerosis of the relapsing remitting type with 2 or more relapses within the last 2 years 22 mcg 3 times weekly
812 Interferon Beta-1a 44 mcg Injection L03AB07000P5002XX A* Multiple sclerosis of the relapsing remitting type with 2 or more relapses within the last 2 years 44 mcg 3 times weekly
813 Iodine and Potassium Iodide Solution H03CA00-200-L99-01-XXX B i) Pre-operative treatment of thyrotoxicosis
ii) Thyrotoxicosis crisis		 None i) 1 ml daily in divided doses
ii) 5-10 drops (6.25mg per drop) every 6-8 hourly
814 Iodixanol 320 mg I/ml Injection V08AB09000P3001XX A X-ray contrast medium for cardioangiography, cerebral angiography, peripheral arteriography, abdominal angiography, uroloraphy, venography, CT enhancement, lumbar, thoracic and cervical myelography Depending on type of examination
815 Iohexol Injection V08AB02-000-P30-01-XXX A X-ray contrast medium for use in adults and children for cardioangiography, arteriography, urography, phlebography and CT-enhancement.

Lumbar, thoracic, cervical myelography and computed tomography of the basal cisterns, following subarachnoid injection.

Arthrography, endoscopic retrograde pancreatography (ERCP), herniography, hysterosalpingography, sialography and studies of the gastrointestinal tract		 - Dose depending on the route and procedure
816 Iopamidol Injection V08AB04000P3001XX A i) Neuroradiology: myeloradiculography, cisternography and ventriculography
ii) Angiograph: cerebral arteriography, thoracic aortography, abdominal aortography, angiocardiography, selective visceral arteriography, peripheral arteriography, venography, digital subtraction angiography (DSA)
iii) Urography
iv) Other diagnostic procedures: Contrast enhancement in CT Scanning, arthrography, fistulography		 Dose depending on the route and procedure.
817 Iopromide 300mg injection (623 mg of iopromide with 300 mg of iodine per mL) V08AB05000P3001XX A i) For angiography, urography, aortography and the visualization of body cavities ii) Contrast enhancement during computerized tomography iii) To check functioning of a dialysis shunt Dose depending on the route and procedure
818 Iopromide 370mg injection (769 mg of iopromide with 370 mg of iodine per mL) V08AB05000P3002XX A i) For angiography, urography, aortography and the visualization of body cavities ii) Contrast enhancement during computerized tomography iii) To check functioning of a dialysis shunt Dose depending on the route and procedure
819 Ipratropium Bromide 0.0125% Nebulising Solution (125 mcg/ml) R03BB01-320-A30-01-XXX B Maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema.
Used concomitantly with inhaled beta-agonists in the treatment of acute bronchospasm associated with chronic obstructive pulmonary disease including chronic bronchitis and asthma.		 None Maintenance treatment:
i) Adult and adolescents over 12 years old: 500mcg per dose, 3 to 4 times daily.
ii) Children 6 - 12 years old: 250mcg per dose, 3 to 4 times daily.
iii) Children less than 6 years old: 100 - 250mcg per dose, 3 to 4 times daily.

Acute attacks (in combination with beta-agonist):
i) Adult and adolescents over 12 years old: 500mcg per dose, time interval between doses may be determined by the physician.
ii) Children 6 - 12 years old: 250mcg per dose, time interval between doses may be determined by the physician.
iii) Children less than 6 years old: 100 - 250mcg per dose, time interval between doses may be determined by the physician.


820 Ipratropium Bromide 0.025% Inhalation Solution (250mcg/ml) R03BB01-320-A30-02-XXX B Maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema.
Used concomitantly with inhaled beta-agonists in the treatment of acute bronchospasm associated with chronic obstructive pulmonary disease including chronic bronchitis and asthma.		 None Maintenance treatment:
i) Adult and adolescents over 12 years old: 500mcg per dose, 3 to 4 times daily.
ii) Children 6 - 12 years old: 250mcg per dose, 3 to 4 times daily.
iii) Children less than 6 years old: 100 - 250mcg per dose, 3 to 4 times daily.

Acute attacks (in combination with beta-agonist):
i) Adult and adolescents over 12 years old: 500mcg per dose, time interval between doses may be determined by the physician.
ii) Children 6 - 12 years old: 250mcg per dose, time interval between doses may be determined by the physician.
iii) Children less than 6 years old: 100 - 250mcg per dose, time interval between doses may be determined by the physician.


821 Ipratropium Bromide 0.5mg and Salbutamol 2.5mg per UDV R03AK04-320-A30-01-XXX B Management of reversible bronchospasm associated with obstructive airway diseases None Acute attacks : 1 unit dose vial. In severe cases not relieved by 1 unit dose vial, 2 unit dose vials may require. Maintenance : 1 unit dose vial 3 - 4 times daily
822 Ipratropium Bromide 20 mcg/dose Inhalation R03BB01-320-A10-01-XXX B Maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis, emphysema and asthma. None Adult and children more than 6 years of age: 2 puffs 4 times daily. Total daily dose of 12 puffs.
823 Ipratropium Bromide 20mcg and Fenoterol 50mcg/dose Inhaler R03AK03-986-A21-01-XXX B Management of symptoms in chronic obstructive airway disorders with reversible bronchospasm such as bronchial asthma and chronic bronchitis with or without emphysema None ADULT & CHILD more than 6 years; Acute asthma 2 puffs. Severe cases: if breathing has not noticeably improved after 5 mins, 2 further puffs may be taken. Intermittent and long-term treatment 1-2 puffs for each administration, up to max 8 puffs/day (average: 1-2 puffs three times daily)
824 Ipratropium Bromide 20mcg and Salbutamol base 100mcg/dose Inhalation R03AK04-320-A10-01-XXX B Management of reversible bronchospasm associated with obstructive airway diseases None ADULT and ELDERLY : 2 inhalations 4 times daily. Maximum : 12 inhalations daily. CHILD under 12 years not recommended
825 Irinotecan HCl Trihydrate 20 mg/ml Injection L01XX19110P3002XX A* Metastatic colorectal cancer In combination therapy (for previously untreated patients): 180 mg/m2 once every 2 weeks as an IV infusion over 90 mins followed by infusion with folinic acid and 5-fluorouracil. In monotherapy (for previously treated patients): 350 mg/m2 administered as an intravenous infusion over 90 minutes period once every 3 weeks
826 Iron (III) hydroxide sucrose complex 20mg/ml solution for injection B03AC02250P3001XX B Treatment of iron deficiency anaemia:
a) where there is a clinical need for rapid iron supply
b) in patients who cannot tolerate oral iron therapy or who are non-compliant
c) in active inflammatory bowel disease where oral iron preparations are ineffective		 ADULT and ELDERLY:
Cumulative dose is to be administered in single doses of 100 - 200 mg of iron 2 - 3 times weekly depending on Hb level.
Total cumulative dose: 1000 mg
827 Iron (III) Polymaltose Complex 10mg iron/ml syrup B03AB05000L9001XX A/KK Treatment of latent iron deficiency and iron deficiency anaemia (manifest iron deficiency). In primary care setting, for pediatrics use only Infants (up to 1 year): 2.5-5ml daily (25-50mg iron)
Children (1-12 years old): 5-10ml daily (50-100mg iron)
Children (>12 years), adults: 10-30 ml daily (100-300mg iron)
Pregnant woman 20-30ml daily (200-300mg iron)
828 Iron (III)-hydroxide polymaltose complex (IPC) 100mg iron and 0.35mg folic acid chewable tablet B03AD04-250-T20-01-XXX A/KK Treatment of iron deficiency without anaemia and iron deficiency anaemia Dosage and duration of therapy are dependent upon the extent of iron deficiency.
Manifest iron deficiency: 1 chewable tablet two to three times daily until a normalization of the hemoglobin value is achieved. Afterwards the therapy should be continued with 1 chewable tablet daily at least until the end of pregnancy to replenish the iron stores.
Latent iron deficiency and prevention of iron and folic acid deficiency: 1 chewable tablet daily
829 Iron Dextran 50mg Fe/ml Injection B03AC06000P3001XX B Severe iron deficiency anaemia An initial test dose of 0.5 ml should be given over the desired route. For severe iron deficiency anaemia, 1-2 ml daily given by deep IM. Dosage is individualized according to total iron deficit
830 Isoflurane Liquid N01AB06000L5001XX B i) Induction and ii) Maintenance of anaesthesia i) Induction- Initiate at a concentration of 0.5 % ii) Maintenance- 1 - 2.5 % in oxygen or nitrous oxide mixture. 0.5 - 0.75 % with oxygen and nitrous oxide for Caesarian section
831 Isoniazid 100 mg Tablet J04AC01-000-T10-01-XXX B i) Tuberculosis
ii)Tuberculous meningitis		 None i) & ii) ADULT 5-8mg/kg daily (Max 300mg) or 15-20mg/kg biweekly (max 1200mg)
832 Isoniazid 400 mg Tablet J04AC01-000-T10-02-XXX B i) Tuberculosis
ii)Tuberculous meningitis		 i) & ii) ADULT 5-8mg/kg daily (Max 300mg) or 15-20mg/kg biweekly (max 1200mg)
833 Isoprenaline HCl 0.2mg/ml Injection C01CA02-110-P30-01-XX B Complete heart block (third-degree artrioventricular block) not responding to atropine, while waiting for cardiac pacing None If given as IM: Initially 0.2 mg (1 ml of 1:5000 solution), followed by 0.02-1 mg depending on clinical response. If given as SC: 0.2 mg (1 ml of 1:5000 solution), followed by 0.15-0.2 mg depending on clinical response. If given as IV : 1-2 mg in 500 ml of dextrose 5%, infused at a rate of 0.5-2 ml/min while the patient's EKG is being monitored. The dose should be titrated to produce the desired clinical response
834 Isoprenaline HCl 1mg/5 ml Injection C01CA02-110-P30-02-XX B Complete heart block (third-degree artrioventricular block) not responding to atropine, while waiting for cardiac pacing None If given as IM: Initially 0.2 mg (1 ml of 1:5000 solution), followed by 0.02-1 mg depending on clinical response. If given as SC: 0.2 mg (1 ml of 1:5000 solution), followed by 0.15-0.2 mg depending on clinical response. If given as IV : 1-2 mg in 500 ml of dextrose 5%, infused at a rate of 0.5-2 ml/min while the patient's EKG is being monitored. The dose should be titrated to produce the desired clinical response
835 Isosorbide Dinitrate 10mg Tablet C01DA08-221-T10-01-XXX B Prophylaxis and treatment for: i) Angina ii) Left ventricular failure None i) 30 - 120 mg daily in divided doses ii) 40 - 160 mg, up to 240 mg if required
836 Isosorbide Dinitrate 1mg/ml Injection C01DA08-221-P30-01-XX A Treatment for angina pectoris and left ventricular failure None 2-12mg IV per hour after dilution.

Dosing is according to product insert or protocol.
837 Isosorbide-5-Mononitrate 60mg SR Tablet C01DA14-221-T50-02-XXX A/KK Angina pectoris None Initial: 30mg daily.
Maintenance: 30-60mg once daily.
Max. 120mg once daily.
838 Isotretinoin 10 mg Capsule D10BA01000C1001XX A* Only for treatment of i) Severe nodulo-cystic acne ii) Acne conglobata iii) Acne fulminans iv) Severe acne vulgaris failing conventional treatment. 0.5-1 mg/kg of body weight per day (in two divided doses) for 15 to 20 weeks; the maximum recommended dose is 2mg/kg of body weight per day. After about 4 weeks, therefore, dosage for the maintenance treatment should be adjusted within the range 0f 0.1-1mg/kg daily to meet individual need. Treatment usually lasts a total of 16 weeks. There should be an interval of at least 8 weeks before re-starting treatment.
839 Isotretinoin 20 mg Capsule D10BA01000C1002XX A* Only for treatment of:
i) Severe nodulo-cystic acne
ii) Acne conglobata
iii) Acne fulminans
iv) Severe acne vulgaris failing conventional treatment
WARNING: THIS DRUG IS TERATOGENIC		 0.5-1 mg/kg of body weight per day (in two divided doses) for 15 to 20 weeks; the maximum recommended dose is 2mg/kg of body weight per day. After about 4 weeks, therefore, dosage for the maintenance treatment should be adjusted within the range 0f 0.1-1mg/kg daily to meet individual need. Treatment usually lasts a total of 16 weeks. There should be an interval of at least 8 weeks before re-starting treatment.
840 Itopride HCl 50mg Tablet A03FA00110T1001XX A* Treatment of gastrointestinal symptoms of functional, non-ulcer dyspepsia (chronic gastritis) i.e sensation of bloating, early satiety, upper abdominal pain or discomfort, anorexia, heartburn, nausea and vomiting 50 mg 3 times daily before meal

Pages